After a quiet summer, trading volumes are soaring as investors pile back into psychedelic stocks.
Exploring the companies and themes that make up this emerging and exciting new sector
Mind Cure adds Alain Roy as a product development specialist
Mind Cure adds a health supplements veteran to its product development team. Moonbeam mushrooms in final product testing.
Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory
Numinus starts psilocybon cultivation operations in its 7,000 sq ft Health Canada-licensed facility.
Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada
Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
Mind Cure Receives Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada
Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
Compass Pathways has closed its IPO financing, raising $146.6 million via the sale of 8,625,000 American Depository Shares.
Psychedelics Stock Warrants Offer Interesting Leverage Play
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
PharmaDrug Inc. Closes Transaction to Acquire First Smart Shop in the Netherlands, Initiates Major Push to Acquire Best of Breed High Traffic Locations
PharmaDrug will assume control of its first Super Smart psychedelics store on October 1st.
MindMed Catches Fire, Seeks To Up-List On NASDAQ
MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
IPOs Drive Big Gains In Psychedelic Stocks
IPO fever is sweeping through the psychedelics space.
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
MindMed Inc has applied to up-list on the NASDAQ.